Fedratinib mechanism of action?

How does fedratinib work in the body?

Fedratinib is a targeted cancer drug that inhibits the JAK2 (Janus kinase 2) signaling pathway. By blocking JAK2, it reduces downstream signaling that would otherwise drive the growth and survival of certain diseased cells. This JAK2 inhibition is the core mechanism behind its therapeutic effect. [1]

What does “JAK2 inhibition” change inside cells?

JAK2 is a key kinase in signaling cascades activated by cytokine receptors. When these pathways are active, they promote transcription of genes involved in proliferation and survival. Fedratinib suppresses that signaling by directly inhibiting JAK2 activity, lowering the cellular signals that support the disease process. [1]

Why does fedratinib target JAK2 specifically?

A major rationale for using a JAK2 inhibitor is that abnormal activation of JAK2 signaling is associated with certain myeloproliferative neoplasms. Fedratinib’s mechanism is designed to counteract that dysregulated JAK2 signaling. [1]

Is fedratinib selective or does it hit other pathways too?

Fedratinib’s described mechanism centers on JAK2 inhibition. The provided information does not specify additional pathway targets beyond JAK2. [1]

Sources

1. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fedratinib